DeepSeq.AI, Inc., a biotechnology company with an innovative generative AI-based platform seeking to transform protein drug discovery with explainable artificial intelligence and data generation at scale, is excited to announce a technology evaluation agreement with Gilead Sciences, Inc. This is the first agreement between the two companies, and will allow Gilead to evaluate DeepSeq.AI's innovative platform and wet lab capabilities, to guide the design and selection of certain high-quality biologics with enhanced specificity and functionality.
"DeepSeq.AI is excited to be working with Gilead to use our platform to accelerate Gilead's design of high-quality biologics," noted Andrew Chang, Ph.D., Co-Founder and CEO of DeepSeq.AI. “We are particularly excited to apply our unique platform, combining advanced library design, large-scale wet-lab screening and DNA sequencing expertise, as part of our explainable Generative AI-based approach."
